Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Parallel-controlled Trial to Compare the Bioequivalence and Safety of the Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody Injection (JHL1101) and Rituximab Injection in CD20 Positive B Cell Lymphoma Patients

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel-controlled Trial to Compare the Bioequivalence and Safety of the Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody Injection (JHL1101) and Rituximab Injection in CD20 Positive B Cell Lymphoma Patients

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2018

At a glance

  • Drugs Rituximab (Primary)
  • Indications B cell lymphoma
  • Focus Pharmacokinetics
  • Sponsors JHL Biotech
  • Most Recent Events

    • 12 Sep 2018 Status changed from planning to not yet recruiting.
    • 05 Jul 2018 According to JHL Biotech media release, the Center for Drug Evaluation (CDE), State Drug Administration of China (SDA) has approved the Phase I Clinical Trial Application for JHL1101 to treat non-Hodgkin lymphoma. JHL will begin the clinical trial in the following months.
    • 17 Jul 2017 According to a JHL Biotech media release, Clinical Trial Application (CTA) for use of JHL1101 in phase I clinical trial in Non-Hodgkins Lymphoma patients is under review by the China Food and Drug Administration (CFDA) Center for Drug Evaluation (CDE).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top